Male Breast Cancer Completed Phase 1 Trials for Lapatinib (DB01259)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01245205Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast CancerTreatment